Pfizer To Buy Certain Animal Health Products From Schering-Plough

DollarSchering-Plough Corp. of Kenilworth, N.J., received the European Commission’s approval Wednesday to sell certain animal health assets to New York-based Pfizer Corp. The assets comprise products for companion and farm animals, including various vaccines, specialty pharmaceuticals and parasiticides.

Schering-Plough is pursuing the sale of these assets following commitments it made to the European Commission late last year in its acquisition of Netherlands-based Organon Biosciences, a subsidiary of Akzo Nobel NV, which includes Intervet International. Schering-Plough had agreed that it would sell more than 20 formulations and trademarks to eliminate antitrust issues.

The European Commission said Wednesday that the transaction between Schering-Plough and Pfizer will not raise competition concerns because “the new entity [Pfizer] would continue to face several significant competitors in all relevant markets for animal vaccines and pharmaceuticals and that farmers and veterinarians across the European Economic Area would continue to have access to alternative suppliers post-merger.”



Leave a Comment



Sign-up for your account with Veterinary Practice News Canada. Your account gives you unlimited free access to our Newsletter Archives and our Digital Editions of Veterinary Practice News Canada.
Please check the box below to confirm you would like to be added to Kenilworth Media’s various e-mail communications (includes e-newsletters, digital editions of the magazine, a survey now and then, and offers to the veterinarian industry*).

Leave this empty:

*We do not sell your e-mail address to 3rd parties, we simply forward their offers to you. Of course, you always have the right to unsubscribe from any communications you receive from us, should you change your mind in the future.